Roche Tries Again With Failed Huntington’s Drug Tominersen
Potential In Younger Adults
Despite disappointment in its Phase III study, Roche is preparing a new trial of the antisense therapy in patients with a lower disease burden.
You may also be interested in...
The company now turns to its next-generation Huntington drug, WVE-003.
The Danish company has the world’s only licensed monkeypox vaccine and is now fielding enquiries from concerned governments from around the world.
Regulators want to help smooth the process of bringing a gene therapy to market, hoping to iron out ‘surprises’ and even address reimbursement issues for the sake of patients.